Navigation Links
Alexza Initiates AZ-104 (Staccato(R) Loxapine) Phase 2b Clinical Trial in Patients With Migraine Headaches
Date:1/20/2009

ndpoint was pain-relief at 2 hours post-administration. AZ-104 met the primary efficacy endpoint of the clinical trial for the two highest doses of the drug compared to placebo. Pain relief was observed in 76.7% of patients at the 5 mg dose (p=0.02), 79.1% of patients at the 2.5 mg dose (p=0.01) and 67.4% of patients at the 1.25 mg dose (p=0.18), compared to 51.3% of patients receiving placebo. AZ-104 was generally safe and well tolerated in this patient population.

About Symphony Allegro

In December 2006, Alexza entered into a collaboration with Symphony Capital LLC, a biotech-focused private equity firm. Under the terms of the agreement, Alexza and Symphony Capital established Symphony Allegro, Inc., which is providing funding to Alexza to accelerate clinical and other related development activities of Staccato loxapine (AZ-004 and AZ-104) and Staccato alprazolam (AZ-002). Alexza has granted a license to certain intellectual property rights for the selected product candidates. Through a purchase option, Alexza retains the exclusive right, but not the obligation, to acquire 100% of the equity of Symphony Allegro at specified prices during the term of the agreement. If Alexza chooses not to exercise the purchase option, Symphony Allegro retains the rights to the product candidates. The purchase option expires December 1, 2010.

About Alexza Pharmaceuticals, Inc.

Alexza Pharmaceuticals is an emerging specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug delivery through deep lung inhalation. The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
4. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
5. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
6. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
7. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
8. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
9. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
10. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
11. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... 15 A Harvard medical expert internationally recognized ... the PGA Tour,s decision last month to suspend ... diagnosed him as having the medical condition ... condition is "unreasonable, unfair and discriminatory." ,, ... normal testosterone levels, often referred to informally as ...
(Date:12/15/2009)... opportune time to find the best plan at the ... Through the end of the year, thousands ... about their health coverage. This is when the ... benefits they will sign up and pay for in ... part of this decision, says Independent Retail Pharmacist Steve ...
(Date:12/15/2009)... Today,s New York Times ... Kidney Drugs Spurs Division," illustrates an internal renal ... patients continuing to be deprived of their life-saving ... limit. ,, As Congress is poised to approve ... lives of transplant kidney recipients, behind-the-scenes debate continues ...
Breaking Medicine Technology:Harvard Medical Expert Criticizes PGA Tour, Calls Decision to Suspend Doug Barron for Doping 'Unreasonable, Unfair and Discriminatory' 2Harvard Medical Expert Criticizes PGA Tour, Calls Decision to Suspend Doug Barron for Doping 'Unreasonable, Unfair and Discriminatory' 3Harvard Medical Expert Criticizes PGA Tour, Calls Decision to Suspend Doug Barron for Doping 'Unreasonable, Unfair and Discriminatory' 4Pharmacist Urges Nebraska Medicare Beneficiaries to Compare Prescription Plans 2AST Concerned That Kidney Transplant Patients May Suffer Politics As Usual in Capitol Hill Health Care Reform Debate 2Teen attitudes toward smoking linked to likelihood of drinking and using drugs 58571 1Teen attitudes toward smoking linked to likelihood of drinking and using drugs 58571 2UNC awarded Cancer Genome Atlas grant 10194 1UNC awarded Cancer Genome Atlas grant 10194 2First human gets new antibody aimed at rabies virus 10189 1First human gets new antibody aimed at rabies virus 10189 2First human gets new antibody aimed at rabies virus 10189 3
... DSM N.V., the global Life Sciences and Materials Sciences company ... that DSM Biomedical obtained an exclusive world-wide license for a ... a San Diego based biomedical company. ... up a broad range of opportunities for next generation drug ...
... LOUISVILLE, Colo., March 11 Preliminary findings from a ... Lipo patients shows 40% to 60% tightening. Patients in ... more body areas with the VASER Lipo System. Skin ... measurements have been taken over a 6 month period."Physicians ...
Other Medicine Technology:DSM Obtains Exclusive World-Wide License for Innovative Drug Delivery Technology 2DSM Obtains Exclusive World-Wide License for Innovative Drug Delivery Technology 3DSM Obtains Exclusive World-Wide License for Innovative Drug Delivery Technology 4Research Shows VASER(R) Lipo Results in Excellent Skin Tightening 2
(Date:12/16/2009)... , , TUESDAY, Dec. 15 (HealthDay News) -- If that ... on your life that you just can,t wait to have ... you might want to wait at least six months before ... be even better. , The study found that when ... chances of the baby dying, being born prematurely, having birth ...
(Date:12/16/2009)... has received a further 1.6 million Euro in capital funding ... System in order to meet the rapidly growing demand for this ... Unisense A/S that continue to own each about 50% of the ... ... -- Unisense FertiliTech A/S has received a further 1.6 million Euro ...
(Date:12/16/2009)... Request A Test, Ltd. is proud to announce being presented with ... Weatherhead 100 showcases the fastest growing companies in Northeast Ohio and ... to succeed. , ... (PRWEB) December ... being presented with the Weatherhead 100 Upstart Award on December 3, ...
(Date:12/16/2009)... & Ennis, P.A. will continue to offer free nationwide confidential ... serious Paxil side effects such as: Birth Defects, Attempted Suicide, ... can call toll free at 1-800-856-6405 or go to the ... online case evaluation form. , ... ...
(Date:12/15/2009)... developed a new electrophoretic method for detecting MIRCERA ... The technique, using SARCOSYL-PAGE, has specifically enhanced sensitivity ... characteristics of SDS-PAGE for detecting other EPOs. ... from the World Anti-Doping Agency (WADA), appear in ... Analysis published by Wiley-Blackwell. , MIRCERA (methoxy ...
Breaking Medicine News(10 mins):Health News:For Babies' Sake, Pregnancy Spacing Matters 2Health News:For Babies' Sake, Pregnancy Spacing Matters 3Health News:Increased Capital Funding for Unisense FertiliTech A/S Will Help Meet Demand for New Assisted Reproduction Device 2Health News:Request A Test Receives Weatherhead 100 Upstart Award 2Health News:Ennis & Ennis, P.A. Announces Nationwide Free Legal Consultations For Users of Paxil 2Health News:Ennis & Ennis, P.A. Announces Nationwide Free Legal Consultations For Users of Paxil 3Health News:Researchers discover novel method for detecting MIRCERA 2
... EL SEGUNDO, Calif., Dec. 27 Computer ... that it has signed an extension to,a ... with Sun Microsystems Inc., Under the ... all,applications development and support services for Sun,s ...
... FDA -, MENLO PARK, Calif., Dec. 27 ... drug-eluting stent (DES),systems, today announced that it has submitted ... Mark approval of its Custom NX DES,System., XTENT,s ... the,drug formulation submission from Biosensors International Group. XTENT,plans to ...
... Dec. 26 Whether it,s living and dying with,every ... the nachos and pizza,that make up the game watching ... of heartburn. Prilosec OTC, the number one selling OTC,heartburn ... opportunity to,win tickets to Super Bowl forty-two in Glendale, ...
... they don,t address benefits of drug therapy , , WEDNESDAY, ... out abnormal heart tissue reduces the number of shocks ... attacks, a new trial showed. , While those shocks ... abnormal rhythms, they are desirable to avoid not only ...
... MELVILLE, N.Y., Dec. 26 Gentiva Health,Services, Inc. (Nasdaq: ... health and related services, announced today that it is,scheduled ... Tuesday, January 8,2008 at the 26th Annual JPMorgan Healthcare ... available to the public via a live audio web ...
... NEW YORK, Dec. 26 Immtech Pharmaceuticals,Inc. (Amex: ... working with clinical,investigators at the South African site ... (DB289), an investigational therapy. In preliminary,findings from the ... following treatment with pafuramidine. The Company has discussed,the ...
Other Medicine News:Health News:CSC Signs Extension to Managed Applications Services Agreement With Sun Microsystems 2Health News:XTENT Submits CE Mark Registration to Market Custom NX(R) Drug-Eluting Stent System in Europe 2Health News:XTENT Submits CE Mark Registration to Market Custom NX(R) Drug-Eluting Stent System in Europe 3Health News:Heart Procedure Reduces Need for Defibrillator Shocks 2Health News:Heart Procedure Reduces Need for Defibrillator Shocks 3Health News:Gentiva(R) Health Services to Present January 8 at JPMorgan Healthcare Conference in San Francisco 2Health News:Gentiva(R) Health Services to Present January 8 at JPMorgan Healthcare Conference in San Francisco 3Health News:Immtech Announces Pafuramidine (DB289) Program on Clinical Hold 2Health News:Immtech Announces Pafuramidine (DB289) Program on Clinical Hold 3
... is a sensitive, simple to ... the detection of all major ... can distinguish between P. ... vivax . In addition, the ...
... is a two site sandwich ... the detection of P. falciparum ... HRP-2) and P. vivax specific ... be used for specific detection ...
The Cellabs Rapimal (P.f.) is a rapid and sensitive in vitro immunochromatography assay system for the detection of HRP-2 antigen produced by P. falciparum at the merozoite (red blood cell) stage o...
An immunochromatographic rapid test for the detection of Plasmodium falciparum in whole blood....
Medicine Products: